X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-01 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $39.03 | -1,168 | 19,157 | -6% | -$45,586 | |||||
| D | 2023-05-30 | KDNY | Greenman William Mariner | Dir | S - Sale+OE | $23.30 | -1,155 | 23,643 | -5% | -$26,912 | |||||
| D | 2023-04-24 | KDNY | Dobmeier Eric | Pres, CEO | S - Sale+OE | $21.61 | -25,000 | 301,138 | -8% | -$540,239 | |||||
2023-04-17 | KDNY | Jerel Davis | Dir | S - Sale | $20.75 | -295,808 | 3,478,920 | -8% | -$6,138,223 | ||||||
| D | 2023-04-03 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $23.34 | -5,000 | 16,992 | -23% | -$116,718 | |||||
| D | 2023-04-04 | KDNY | Krishnan Mahesh | Dir | S - Sale+OE | $23.01 | -924 | 1,275 | -42% | -$21,261 | |||||
2023-03-01 | KDNY | Jerel Davis | Dir | S - Sale | $22.75 | -400,000 | 950,517 | -30% | -$9,100,000 | ||||||
| D | 2023-02-10 | KDNY | Bjerkholt Eric | CFO | S - Sale+OE | $23.75 | -857 | 38,867 | -2% | -$20,352 | |||||
| D | 2023-02-10 | KDNY | Dobmeier Eric | Pres, CEO | S - Sale+OE | $23.75 | -8,097 | 301,138 | -3% | -$192,292 | |||||
| D | 2023-02-10 | KDNY | Frohlich Tom | COO | S - Sale+OE | $23.75 | -3,700 | 150,777 | -2% | -$87,869 | |||||
| D | 2023-02-10 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $23.75 | -2,392 | 19,492 | -11% | -$56,806 | |||||
| D | 2023-01-31 | KDNY | Frohlich Tom | COO | S - Sale+OE | $24.68 | -4,566 | 147,674 | -3% | -$112,700 | |||||
| D | 2023-01-31 | KDNY | Bjerkholt Eric | CFO | S - Sale+OE | $24.68 | -2,891 | 37,289 | -7% | -$71,357 | |||||
| D | 2023-01-31 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $24.68 | -3,244 | 15,081 | -18% | -$80,069 | |||||
| DM | 2023-01-30 | KDNY | Dobmeier Eric | Pres, CEO | S - Sale+OE | $24.58 | -32,688 | 288,987 | -10% | -$803,369 | |||||
| D | 2023-01-03 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $25.82 | -10,000 | 9,992 | -50% | -$258,183 | |||||
| D | 2022-12-13 | KDNY | Frohlich Tom | COO | S - Sale+OE | $25.00 | -10,000 | 143,907 | -6% | -$250,005 | |||||
| D | 2022-12-01 | KDNY | Dobmeier Eric | Pres, CEO | S - Sale+OE | $22.31 | -30,000 | 241,676 | -11% | -$669,351 | |||||
| D | 2022-12-01 | KDNY | Bjerkholt Eric | CFO | S - Sale+OE | $22.29 | -5,770 | 32,847 | -15% | -$128,602 | |||||
| D | 2022-11-07 | KDNY | Frohlich Tom | COO | S - Sale+OE | $22.16 | -10,000 | 143,907 | -6% | -$221,642 | |||||
| D | 2022-10-06 | KDNY | Frohlich Tom | COO | S - Sale+OE | $19.69 | -7,360 | 143,907 | -5% | -$144,933 | |||||
| D | 2022-10-06 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $19.69 | -3,557 | 12,492 | -22% | -$70,044 | |||||
2022-09-02 | KDNY | Thomas Dolca | Dir | P - Purchase | $21.22 | +10,000 | 10,000 | New | +$212,194 | ||||||
| D | 2022-08-04 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $20.00 | -5,000 | 5,897 | -46% | -$100,000 | |||||
| D | 2022-07-11 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $18.09 | -5,000 | 5,897 | -46% | -$90,468 | |||||
2022-05-27 | KDNY | Akkaraju Srinivas | Dir | P - Purchase | $14.00 | +570,000 | 5,161,888 | +12% | +$7,980,000 | ||||||
2022-05-25 | KDNY | Dobmeier Eric | Pres, CEO | P - Purchase | $13.03 | +5,000 | 205,880 | +2% | +$65,148 | ||||||
| D | 2022-04-11 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $15.36 | -5,000 | 5,897 | -46% | -$76,812 | |||||
2022-02-18 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale | $13.00 | -2,500 | 5,897 | -30% | -$32,500 | ||||||
| D | 2022-02-11 | KDNY | Bjerkholt Eric | CFO | S - Sale+OE | $12.74 | -895 | 22,203 | -4% | -$11,403 | |||||
| D | 2022-02-11 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $12.74 | -2,498 | 8,397 | -23% | -$31,827 | |||||
| D | 2022-02-11 | KDNY | Glicklich Alan | Chief Medical Officer | S - Sale+OE | $12.74 | -2,391 | 7,891 | -23% | -$30,464 | |||||
| D | 2022-02-11 | KDNY | Frohlich Tom | COO | S - Sale+OE | $12.74 | -3,735 | 137,685 | -3% | -$47,587 | |||||
| D | 2022-02-10 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $13.31 | -2,500 | 4,094 | -38% | -$33,275 | |||||
2022-01-03 | KDNY | Versant Venture Capital Vii, L.P. | 10% | S - Sale | $16.00 | -1,000,000 | 4,175,172 | -19% | -$16,000,200 | ||||||
2022-01-03 | KDNY | Jerel Davis | Dir, 10% | S - Sale | $16.00 | -1,000,000 | 552,149 | -64% | -$16,000,200 | ||||||
2021-11-15 | KDNY | Akkaraju Srinivas | Dir | P - Purchase | $14.00 | +1,215,000 | 4,591,888 | +36% | +$17,010,000 | ||||||
2021-11-10 | KDNY | Frohlich Tom | COO | S - Sale | $15.48 | -6,230 | 134,619 | -4% | -$96,440 | ||||||
| D | 2021-11-09 | KDNY | King Andrew James | Chief Scientific Officer | S - Sale+OE | $13.53 | -5,000 | 4,094 | -55% | -$67,660 | |||||
| DM | 2021-11-05 | KDNY | Frohlich Tom | COO | S - Sale+OE | $14.48 | -33,770 | 140,849 | -19% | -$488,938 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |